GFRA2 - GDNF Family Receptor Alpha 2
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">GFRA2 - GDNF Family Receptor Alpha 2</th>
</tr>
<tr>
<td class="label">Receptor</td>
<td>Primary Ligand</td>
</tr>
<tr>
<td class="label">GFRα1</td>
<td>GDNF</td>
</tr>
<tr>
<td class="label">GFRα2</td>
<td>Neurturin</td>
</tr>
<tr>
<td class="label">GFRα3</td>
<td>Artemin</td>
</tr>
<tr>
<td class="label">GFRα4</td>
<td>GDNF-like (fish)</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">Signal peptide</td>
<td>1-21</td>
</tr>
<tr>
<td class="label">Propeptide</td>
<td>22-29</td>
</tr>
<tr>
<td class="label">Extracellular domain</td>
<td>30-330</td>
</tr>
<tr>
<td class="label">LFHL domains</td>
<td>60-330</td>
</tr>
<tr>
<td class="label">GPI anchor</td>
<td>C-terminus</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">Gene therapy</td>
<td>AAV2-NRTN (CERE-120)</td>
</tr>
<tr>
<td class="label">Protein delivery</td>
<td>Recombinant NRTN</td>
</tr>
<tr>
<td class="label">Small molecules</td>
<td>RET agonists</td>
</tr>
<tr>
<td class="label">Cell therapy</td>
<td>NRTN-expressing cells</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Sample</td>
</tr>
<tr>
<td class="label">GFRA2 expression</td>
<td>Brain tissue</td>
</tr>
<tr>
<td class="label">NRTN levels</td>
<td>CSF</td>
</tr>
<tr>
<td class="label">p-AKT signaling</td>
<td>Blood/CSF</td>
</tr>
<tr>
<td class="label">RET phosphorylation</td>
<td>Models</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
GFRA2 (GDNF Family Receptor Alpha 2, also known as GFRα2) is a critical GPI-anchored cell surface receptor that mediates the biological effects of neurturin (NRTN) and other GDNF family ligands. As a key component of the GDNF family signaling system, GFRA2 plays essential roles in the development, survival, and maintenance of dopaminergic neurons, motor neurons, and peripheral neurons.
In the context of neurodegenerative diseases, the GFRA2/neurturin signaling axis has been extensively studied as a therapeutic target for Parkinson's disease, with clinical trials investigating gene therapy approaches to deliver neurotrophic support to degenerating dopaminergic neurons[@bartus2017][@parkinsons2015].
Overview
The GFRA2 receptor is a member of the GDNF receptor alpha (GFRα) family, which includes four related proteins (GFRα1-4) that serve as high-affinity receptors for GDNF family ligands[@gdnfret2001]:
GFRA2 is unique among the GFRα family for its restricted expression pattern and specific role in neuronal survival. It signals primarily through the RET receptor tyrosine kinase to activate pro-survival pathways including PI3K/Akt and MAPK/ERK[@biology2019].
Structure
Protein Architecture
GFRA2 is a approximately 40-45 kDa GPI-anchored protein with distinct structural features:
Mermaid diagram (expand to render)
Domain Organization
Ligand Binding
GFRA2 binds neurturin with high affinity (Kd ~10-20 pM) through its extracellular domain:
- Three LFHL (LGF, FSC1, Hesperdin) modules form the ligand-binding interface
- The binding site is distinct from GFRα1
- Neurturin binding induces GFRA2 dimerization
Post-Translational Modifications
GFRA2 undergoes several modifications:
- N-linked glycosylation: Multiple sites in extracellular domain
- GPI anchor addition: C-terminal signal for membrane attachment
- Proteolytic cleavage: Can release soluble receptor forms
Normal Function
Signaling Mechanisms
GFRA2 mediates neurturin signaling through two primary mechanisms [@paratcha2002][@neurotrophins2003]:
Mermaid diagram (expand to render)
RET-Dependent Signaling
When neurturin binds to GFRA2:
GFRA2 dimerizes and recruits RET
RET autophosphorylates on tyrosine residues
Downstream pathways are activatedPI3K/Akt Pathway:
- Activates Akt (PKB)
- Promotes cell survival
- Inhibits pro-apoptotic proteins
- Activates mTORC1
MAPK/ERK Pathway:
- Activates Ras/Raf/MEK/ERK cascade
- Promotes neuronal differentiation
- Regulates gene expression
- Supports long-term survival
Biological Functions
In the normal nervous system, GFRA2/neurturin signaling supports [@other1998]:
Dopaminergic Neuron Survival
- Promotes survival of substantia nigra pars compacta neurons
- Maintains tyrosine hydroxylase expression
- Supports dendrite arborization
Motor Neuron Function
- Supports facial nucleus motor neurons
- Promotes spinal cord motor neuron survival
- Maintains neuromuscular junctions
Enteric Nervous System
- Essential for enteric neuron development
- Supports gut motility
- Maintains neuronal populations
Peripheral Neurons
- Sympathetic neuron survival
- Sensory neuron support
- Parasympathetic neuron maintenance
Non-neuronal Functions
- Kidney development (minor role)
- Testicular function
- Cancer cell biology
Role in Neurodegenerative Diseases
Parkinson's Disease
GFRA2/neurturin is one of the most studied neurotrophic systems in PD [@aavmediated2011][@randomized2006]:
Rationale for therapy:
- GDNF and neurturin support dopaminergic neuron survival
- PD involves progressive loss of substantia nigra neurons
- Neurotrophic factors could slow or halt degeneration
Clinical trials:
- CERE-120 (AAV2-NRTN): Gene therapy delivering neurturin
- Phase I/II trials showed some motor improvements
- Phase IIb failed to meet primary endpoint
- Post-hoc analysis suggested benefit in younger patients
- Direct GDNF infusion: Multiple trials (Amgen, NINDS)
- Showed promising results in some patients
- Delivery challenges limited efficacy
Current status:
- Newer AAV vectors being developed
- Combination approaches with other neurotrophic factors
- Cell-based delivery systems under investigation
Amyotrophic Lateral Sclerosis
GFRA2 in ALS [@neurotrophic2009]:
Motor neuron support:
- Neurturin can protect motor neurons
- Supports neuromuscular junction integrity
- May delay disease progression
Therapeutic potential:
- AAV-NRTN being studied
- Combination with other neurotrophic factors
- Gene therapy approaches
Other Neurodegenerative Disorders
Peripheral neuropathies:
- GFRA2 supports sensory neurons
- Being explored for diabetic neuropathy
- Charcot-Marie-Tooth disease research
Enteric neurodegeneration:
- Hirschsprung disease association
- Gut motility disorders
Therapeutic Targeting
Neurotrophic Factor Therapy
Challenges
Key challenges in targeting GFRA2 for neurodegeneration [@tdwells2019]:
Delivery: Getting neurotrophic factors to the brain
Blood-brain barrier: Limited CNS penetration
Dosing: Optimal dose unclear
Patient selection: Biomarkers needed
Timing: When to treat in disease course
Safety: Potential off-target effectsFuture Directions
- New viral vectors with improved tropism
- Targeted delivery to specific brain regions
- Combination with neuroprotective drugs
- Biomarker development for patient selection
Biomarkers
Clinical Correlations
GFRA2 biomarkers may indicate:
- Patient suitability for neurotrophic therapy
- Treatment response
- Disease progression
Cross-Pathway Interactions
GFRA2 intersects with multiple neurodegenerative pathways [@gdnfret2015]:
Mermaid diagram (expand to render)
- Mitochondrial function: Pro-survival signaling
- Autophagy: Regulation of protein clearance
- Synaptic plasticity: Support of synaptic connections
- Neuroinflammation: Modulation of glial responses
Background
The study of Gfra2 Gdnf Family Receptor Alpha 2 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- GDNF Family Neurotrophic Factor Signaling Pathway
- Neurturin (NRTN) Protein
- RET Receptor Tyrosine Kinase
- [Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
- Parkinson's Disease Gene Therapy
- Dopaminergic Neuron Survival
External Links
- [GFRA2 Gene - NCBI](https://www.ncbi.nlm.nih.gov/gene/2675)
- [UniProt O00509 - GFRA2](https://www.uniprot.org/uniprot/O00509)
- [GDNF Family - R&D Systems](https://www.rndsystems.com/categories/gdnf-family)
References
[- Airaksinen MS, Saarma M, "The GDNF family: signalling, biological functions and therapeutic value." Nature Reviews Neuroscience (2002)](https://pubmed.ncbi.nlm.nih.gov/11988777/)
[- Baloh RH, Enomoto H, Johnson EM Jr, Milbrandt J, "The GDNF family ligands and receptors." Current Opinion in Neurobiology (2000)](https://pubmed.ncbi.nlm.nih.gov/10679430/)
[Unknown, - Bartus RT, Johnson EM Jr. "Clinical tests of neurotrophic factors for human neurodegenerative diseases." Neurobiology of Disease. 2017;97:97-109 (2017)](https://pubmed.ncbi.nlm.nih.gov/27452340/)
[- Kalia LV, Lang AE, "Parkinson's disease." Lancet (2015)](https://pubmed.ncbi.nlm.nih.gov/25904081/)
[- Takahashi M, "The GDNF/RET signaling pathway and human diseases." Cytokine & Growth Factor Reviews (2001)](https://pubmed.ncbi.nlm.nih.gov/11714563/)
[- Ibáñez CF, Andressoo JO, "Biology of GDNF and its receptors - relevance to disorders of the central nervous system." Handbook of Experimental Pharmacology (2019)](https://pubmed.ncbi.nlm.nih.gov/30809752/)
[Unknown, - Paratcha G, Ibáñez CF. "GDNF and GFRα: a versatile neuronal unit signaling machine." Nature Reviews Neuroscience. 2002;3(5):382-394 (2002)](https://pubmed.ncbi.nlm.nih.gov/11988776/)
[- Chao MV, "Neurotrophins and their receptors: a convergence point for many signalling pathways." Nature Reviews Neuroscience (2003)](https://pubmed.ncbi.nlm.nih.gov/12671746/)
- Saarma M, Sariola H, "Other neurotrophic factors: GDNF and NTN." Mental Retardation and Developmental Disabilities Research Reviews (1998)
[- Bartus RT, Brown L, Pérez A, et al, "AAV2-mediated gene therapy for neurotrophic factor delivery." Molecular Therapy (2011)](https://pubmed.ncbi.nlm.nih.gov/21427708/)
[- Lang AE, Gill S, Patel NK, et al, "Randomized controlled trial of intraputaminal GDNF infusion." Annals of Neurology (2006)](https://pubmed.ncbi.nlm.nih.gov/16491659/)
[- Sakowski SA, Levenstuen BA, Kim E, et al, "Neurotrophic factors and ALS." Experimental Neurology (2009)](https://pubmed.ncbi.nlm.nih.gov/19703545/)
[-邮箱:TDwells J, Barker RA, "Clinical trials of neurotrophic factors for Parkinson's disease." Movement Disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/30957323/)
[- Kramer ER, Liss B, "GDNF/RET signaling in Parkinson's disease." Journal of Neural Transmission (2015)](https://pubmed.ncbi.nlm.nih.gov/25740052/)